Holen Sie sich die Stockscreener-App
94.15
0.51%
0.48
Vorhandelsmarkt:
94.00
-0.15
-0.16%
Merus N V Aktie (MRUS) Neueste Nachrichten
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V.MRUS - The AI Journal
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS) - PR Newswire
Latham & Watkins Advises Merus in US$8 Billion Acquisition by Genmab - Latham & Watkins LLP
Genmab Nears Deal to Buy Cancer Drugmaker Merus - MSN
This Maplebear Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
MRUS Analyst Rating Update: Guggenheim Downgrades to Neutral | M - GuruFocus
MRUS Analyst Rating Update: Canaccord Genuity Adjusts PT and Rat - GuruFocus
Merus (MRUS) Sees Rating Downgrade and Target Price Raise by Wells Fargo | MRUS Stock News - GuruFocus
Merus (MRUS) Receives Rating Downgrade by LifeSci Capital | MRUS Stock News - GuruFocus
Barclays Downgrades MRUS, Lowers Price Target Amid Market Adjustments | MRUS Stock News - GuruFocus
Merus (MRUS) Sees Downgrade from UBS with Raised Price Target | MRUS Stock News - GuruFocus
Merus (NASDAQ:MRUS) Receives "Market Perform" Rating from Lifesci Capital - MarketBeat
Barclays Downgrades Merus to Equalweight From Overweight, Adjusts Price Target to $97 From $112 - MarketScreener
BMO Capital Downgrades Merus to Market Perform From Outperform, Adjusts Price Target to $97 From $110 - MarketScreener
Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal - Stocktwits
Merus (NASDAQ:MRUS) Rating Lowered to "Hold" at Wells Fargo & Company - MarketBeat
Genmab Bets Big On Cancer With $8 Billion Merus Deal - Finimize
Merus Reaches Analyst Target Price - Nasdaq
How big funds are accumulating Merus N.V. (2GH) stock2025 Sector Review & Proven Capital Preservation Methods - newser.com
MRUS Stock Downgraded: HC Wainwright & Co. Lowers Price Target | - GuruFocus
Genmab to acquire Merus shares for $8bn - Yahoo Finance
Barclays downgrades Merus stock to Equalweight, cuts price target on valuation - Investing.com
Guggenheim downgrades Merus stock to Neutral following Genmab acquisition - Investing.com
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - AD HOC NEWS
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction - Yahoo Finance
EQT Is Shareholder in Merus, Acquired by Denmark's Genmab - MarketScreener
Merus stock rating downgraded by UBS after Genmab acquisition - Investing.com India
Genmab to acquire Merus for $8 billion in cash deal By Investing.com - Investing.com Australia
What’s the recovery path for long term holders of Merus N.V.Market Volume Report & Smart Money Movement Alerts - newser.com
Is Merus N.V. building a consolidation base2025 Winners & Losers & High Win Rate Trade Tips - newser.com
Genmab to acquire Merus for $8 billion in cash deal - Investing.com
What margin trends mean for Merus N.V. stockWeekly Trend Report & High Conviction Buy Zone Picks - newser.com
Genmab swallows Merus in US$8bn deal - European Biotechnology Magazine
Genmab adding late-stage bispecific in $8B Merus acquisition - BioWorld MedTech
Mid Cap Stocks To ConsiderSeptember 29th - MarketBeat
Will Merus N.V. stock see PE expansionLong Setup & Risk Adjusted Swing Trade Ideas - newser.com
Merus N.V. Stock: Analyzing Recent Fluctuations - timothysykes.com
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes - FinancialContent
Leadership Changes and Bold Moves Shake Global Drugmakers - Devdiscourse
Merus (MRUS) Experiences Surge with Significant Stock Price Incr - GuruFocus
Genmab’s $8B Merus takeout is latest push toward full ownership of programs - biocentury.com
Can Merus Sustain The Leap? - StocksToTrade
Transcript : Genmab A/S, Merus N.V.M&A Call - MarketScreener
MRUS: Truist Securities Downgrades Rating, Raises Price Target | MRUS Stock News - GuruFocus
Promising Medical Stocks To Keep An Eye OnSeptember 29th - MarketBeat
Genmab to Acquire Merus in $8 Billion Biotech Deal - USA Herald
MRUS Shares Surge Amid Acquisition Talks - timothysykes.com
4 Firms Advise On Genmab's $8B Merus Acquisition Plan - Law360
HC Wainwright Downgrades Merus to Neutral From Buy, Price Target at $97 - MarketScreener
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders - Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
A&O Shearman advises Genmab on its proposed USD8 billion acquisition of Merus - A&O Shearman
Genmab to buy Dutch cancer drugmaker Merus for $8 billion - Reuters
Genmab Makes $8 Billion Bet On Cancer Drugmaker Merus - Finimize
Canaccord Genuity Downgrades Merus to Hold From Buy, Price Target is $97 - MarketScreener
Genmab Makes A Big Bet With Merus N.V. Acquisition (NASDAQ:GMAB) - Seeking Alpha
Merus (MRUS): Wells Fargo Downgrades and Raises Price Target | M - GuruFocus
Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline - CryptoRank
Merus (NASDAQ:MRUS) Hits New 12-Month HighTime to Buy? - MarketBeat
MRUS Downgraded by Needham to Hold, Maintains Price Target of $9 - GuruFocus
Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue (MRUS) - Seeking Alpha
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):